Subscribe
zerbor
4 June 2018Big Pharma

French court knocks out Gilead Truvada SPC

The Paris Court of First Instance has nullified a supplementary protection certificate (SPC) covering Gilead’s HIV/AIDS treatment Truvada.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Europe
Gilead HIV drug not entitled to SPC, says UK court
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
French court refuses MSD injunction request in SPC clash
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.


Editor's picks

AstraZeneca unit faces class-action suit over alleged Soliris monopoly
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

Editor's picks

Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025

More on this story

Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Europe
Gilead HIV drug not entitled to SPC, says UK court
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
French court refuses MSD injunction request in SPC clash
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.

More on this story

Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Europe
Gilead HIV drug not entitled to SPC, says UK court
20 September 2018   The English High Court has ruled that Gilead’s drug Truvada is not entitled to a supplementary protection certificate because it failed to meet the standards set out by Europe’s highest court earlier this year.
Big Pharma
French court refuses MSD injunction request in SPC clash
10 July 2018   The Paris Court of Appeal has refused to grant Merck Sharp & Dohme a preliminary injunction based on a supplementary protection certificate against French pharmaceutical company Biogaran.

More features

South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency
Fenwick establishes new Boston office with trio of IP partners from Cooley
How pharma should prep for the six-bill avalanche from Congress
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
USPTO speeds up patent issuance amid widespread agency changes
Lathrop GPM adds portfolio management specialist